The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.
Amita Patnaik
No relevant relationships to disclose
Patricia LoRusso
Research Funding - Astellas Pharma
Howard A. Ball
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Erkut Bahceci
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Geoffrey Yuen
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
Kyriakos P. Papadopoulos
Research Funding - Astellas Pharma
Muaiad Kittaneh
Research Funding - Astellas Pharma
Anthony W. Tolcher
Research Funding - Astellas Pharma